Aminophenols: Phenols substituted in any position by an amino group.Neoprene: An oil-resistant synthetic rubber made by the polymerization of chloroprene.Aminobenzoates: Derivatives of BENZOIC ACID that contain one or more amino groups attached to the benzene ring structure. Included under this heading are a broad variety of acid forms, salts, esters, and amides that include the aminobenzoate structure.Hydroxylamines: Organic compounds that contain the (-NH2OH) radical.Hydroxybenzoates: Benzoate derivatives substituted by one or more hydroxy groups in any position on the benzene ring.Aniline CompoundsDioxygenases: Non-heme iron-containing enzymes that incorporate two atoms of OXYGEN into the substrate. They are important in biosynthesis of FLAVONOIDS; GIBBERELLINS; and HYOSCYAMINE; and for degradation of AROMATIC HYDROCARBONS.NitrophenolsPseudomonas: A genus of gram-negative, aerobic, rod-shaped bacteria widely distributed in nature. Some species are pathogenic for humans, animals, and plants.Pseudomonas putida: A species of gram-negative, aerobic bacteria isolated from soil and water as well as clinical specimens. Occasionally it is an opportunistic pathogen.Oxygenases: Oxidases that specifically introduce DIOXYGEN-derived oxygen atoms into a variety of organic molecules.Burkholderia: A genus of gram-negative, aerobic, rod-shaped bacteria. Organisms in this genus had originally been classified as members of the PSEUDOMONAS genus but overwhelming biochemical and chemical findings indicated the need to separate them from other Pseudomonas species, and hence, this new genus was created.Metabolomics: The systematic identification and quantitation of all the metabolic products of a cell, tissue, organ, or organism under varying conditions. The METABOLOME of a cell or organism is a dynamic collection of metabolites which represent its net response to current conditions.Canada: The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.Alberta: A province of western Canada, lying between the provinces of British Columbia and Saskatchewan. Its capital is Edmonton. It was named in honor of Princess Louise Caroline Alberta, the fourth daughter of Queen Victoria. (From Webster's New Geographical Dictionary, 1988, p26 & Room, Brewer's Dictionary of Names, 1992, p12)British Columbia: A province of Canada on the Pacific coast. Its capital is Victoria. The name given in 1858 derives from the Columbia River which was named by the American captain Robert Gray for his ship Columbia which in turn was named for Columbus. (From Webster's New Geographical Dictionary, 1988, p178 & Room, Brewer's Dictionary of Names, 1992, p81-2)Genomics: The systematic study of the complete DNA sequences (GENOME) of organisms.Health Records, Personal: Longitudinal patient-maintained records of individual health history and tools that allow individual control of access.CresolsChlorophenols: Phenols substituted with one or more chlorine atoms in any position.Phenol: An antiseptic and disinfectant aromatic alcohol.Crown Ethers: Macrocyclic polyethers with the repeating unit of (-CH2-CH2-O)n where n is greater than 2 and some oxygens may be replaced by nitrogen, sulfur or phosphorus. These compounds are useful for coordinating CATIONS. The nomenclature uses a prefix to indicate the size of the ring and a suffix for the number of heteroatoms.Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.Mutagenicity Tests: Tests of chemical substances and physical agents for mutagenic potential. They include microbial, insect, mammalian cell, and whole animal tests.Counterfeit Drugs: Drugs manufactured and sold with the intent to misrepresent its origin, authenticity, chemical composition, and or efficacy. Counterfeit drugs may contain inappropriate quantities of ingredients not listed on the label or package. In order to further deceive the consumer, the packaging, container, or labeling, may be inaccurate, incorrect, or fake.Homogentisic AcidFraud: Exploitation through misrepresentation of the facts or concealment of the purposes of the exploiter.MethemoglobinChina: A country spanning from central Asia to the Pacific Ocean.Directories as Topic: Lists of persons or organizations, systematically arranged, usually in alphabetic or classed order, giving address, affiliations, etc., for individuals, and giving address, officers, functions, and similar data for organizations. (ALA Glossary of Library and Information Science, 1983)Research Report: Detailed account or statement or formal record of data resulting from empirical inquiry.Salmonella enterica: A subgenus of Salmonella containing several medically important serotypes. The habitat for the majority of strains is warm-blooded animals.Salmonella typhimurium: A serotype of Salmonella enterica that is a frequent agent of Salmonella gastroenteritis in humans. It also causes PARATYPHOID FEVER.Salmonella: A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria that utilizes citrate as a sole carbon source. It is pathogenic for humans, causing enteric fevers, gastroenteritis, and bacteremia. Food poisoning is the most common clinical manifestation. Organisms within this genus are separated on the basis of antigenic characteristics, sugar fermentation patterns, and bacteriophage susceptibility.Salmonella Infections: Infections with bacteria of the genus SALMONELLA.Salmonella Infections, Animal: Infections in animals with bacteria of the genus SALMONELLA.Terminology as Topic: The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.Safety: Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.Accidents, Occupational: Unforeseen occurrences, especially injuries in the course of work-related activities.Databases, Chemical: Databases devoted to knowledge about specific chemicals.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Heparitin Sulfate: A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS.Dictionaries, ChemicalEpoxy Resins: Polymeric resins derived from OXIRANES and characterized by strength and thermosetting properties. Epoxy resins are often used as dental materials.Resins, Plant: Flammable, amorphous, vegetable products of secretion or disintegration, usually formed in special cavities of plants. They are generally insoluble in water and soluble in alcohol, carbon tetrachloride, ether, or volatile oils. They are fusible and have a conchoidal fracture. They are the oxidation or polymerization products of the terpenes, and are mixtures of aromatic acids and esters. Most are soft and sticky, but harden after exposure to cold. (From Grant & Hackh's Chemical Dictionary, 5th ed & Dorland, 28th ed)Monomethylhydrazine: Hydrazine substituted by one methyl group.Epoxy Compounds: Organic compounds that include a cyclic ether with three ring atoms in their structure. They are commonly used as precursors for POLYMERS such as EPOXY RESINS.Halogens: A family of nonmetallic, generally electronegative, elements that form group 17 (formerly group VIIa) of the periodic table.Marketing: Activity involved in transfer of goods from producer to consumer or in the exchange of services.Foundations: Organizations established by endowments with provision for future maintenance.Dietetics: The application of nutritional principles to regulation of the diet and feeding persons or groups of persons.Journalism, Medical: The collection, writing, and editing of current interest material on topics related to biomedicine for presentation through the mass media, including newspapers, magazines, radio, or television, usually for a public audience such as health care consumers.Publications: Copies of a work or document distributed to the public by sale, rental, lease, or lending. (From ALA Glossary of Library and Information Science, 1983, p181)

Functional heterogeneity of UDP-glucuronosyltransferase as indicated by its differential development and inducibility by glucocorticoids. Demonstration of two groups within the enzyme's activity towards twelve substrates. (1/178)

1. UDP-glucuronosyltransferase activity towards 12 substrates has been assessed in rat liver during the perinatal period. 2. Between days 16 and 20 of gestation, enzyme activities towards the substrates 2-aminophenol, 2-aminobenzoate, 4-nitrophenol, 1-naphthol, 4-methylumbelliferone and 5-hydroxytryptamine (the 'late foetal' group) surge to reach adult values, while activities towards bilirubin, testosterone, beta-oestradiol, morphine, phenolphthalein, and chloramphenicol (the 'neonatal' group) remain negligible or at less than 10% of adult values. 3. By the second postnatal day, enzyme activities towards the neonatal group have attained, or approached adult values. 4. Dexamethasone precociously stimulates in 17-day foetal liver in utero transferase activities in the late foetal, but not the neonatal group. A similar inductive pattern is found for 15-day foetal liver in organ culture. 5. It is suggested that foetal glucocorticoids, whose synthesis markedly increases between days 16 and 20 of gestation, are responsibile for triggering the simultaneous surge of all the hepatic UDP-glucuronosyltransferase activities in the late foetal group. The neonatal group of activities apparently require a different or additional stimulus for their appearance. 6. The relationship of these two groups of transferase activities to other similar groups observed during induction by xenobiotics and enzyme purification is discussed.  (+info)

Potent and selective human beta(3)-adrenergic receptor antagonists. (2/178)

Although the functional presence of beta(3)-adrenergic receptors (beta(3)-AR) in rodents is well established, its significance in human adipose tissue has been controversial. One of the issues confounding the experimental data has been the lack of potent and selective human beta(3)-AR ligands analogous to the rodent-specific agonist BRL37344. Recently, we described a new class of aryloxypropanolamine beta(3)-AR agonists that potently and selectively activate lipolysis in rhesus isolated adipocytes and stimulate the metabolic rate in rhesus monkeys in vivo. In this article, we describe novel and selective beta(3)-AR antagonists with high affinity for the human receptor. L-748,328 and L-748,337 bind the human cloned beta(3)-AR expressed in Chinese hamster ovary (CHO) cells with an affinity of 3.7 +/- 1.4 and 4.0 +/- 0.4 nM, respectively. They display an affinity of 467 +/- 89 and 390 +/- 154 nM for the human beta(1)-AR. Their selectivity for human beta(3)-AR versus beta(2)-AR is greater than 20-fold (99 +/- 43 nM) and 45-fold (204 +/- 75 nM), respectively. These compounds are competitive antagonists capable of inhibiting the functional activation of agonists in a dose-dependent manner in cells expressing human cloned beta(3)-AR. Moreover, both L-748,328 and L-748,337 inhibit the lipolytic response elicited by the beta(3)-AR agonist L-742,791 in isolated nonhuman primate adipocytes. The aryloxypropanolamine benzenesulfonamide ligands illustrated here and elsewhere demonstrate high-affinity human beta(3)-AR binding. In addition, we describe specific 3'-phenoxy substitutions that transform these compounds from potent agonists into selective antagonists.  (+info)

Characterization of hydroxylaminobenzene mutase from pNBZ139 cloned from Pseudomonas pseudoalcaligenes JS45. A highly associated SDS-stable enzyme catalyzing an intramolecular transfer of hydroxy groups. (3/178)

Hydroxylaminobenzene mutase is the enzyme that converts intermediates formed during initial steps in the degradation of nitrobenzene to a novel ring-fission lower pathway in Pseudomonas pseudoalcaligenes JS45. The mutase catalyzes a rearrangement of hydroxylaminobenzene to 2-aminophenol. The mechanism of the reactions and the properties of the enzymes are unknown. In crude extracts, the hydroxylaminobenzene mutase was stable at SDS concentrations as high as 2%. A procedure including Hitrap-SP, Hitrap-Q and Cu(II)-chelating chromatography was used to partially purify the enzyme from an Escherichia coli clone. The partially purified enzyme was eluted in the void volume of a Superose-12 gel-filtration column even in the presence of 0.05% SDS in 25 mM Tris/HCl buffer, which indicated that it was highly associated. When the enzymatic conversion of hydroxylaminobenzene to 2-aminophenol was carried out in 18O-labeled water, the product did not contain 18O, as determined by GC-MS. The results indicate that the reaction proceeded by intramolecular transfer of the hydroxy group from the nitrogen to the C-2 position of the ring. The mechanism is clearly different from the intermolecular transfer of the hydroxy group in the non-enzymatic Bamberger rearrangement of hydroxylaminobenzene to 4-aminophenol and in the enzymatic hydroxymutation of chorismate to isochorismate.  (+info)

Artificial DNAs with metal-assisted base pairs. (4/178)

Two types of artificial beta-C-nucleosides, 2 and 3, were newly synthesized, which possess a metal chelating site (2-aminophenol and catechol, respectively) at the nucleobase moiety. These nucleosides are expected to form metal-assisted base pairs in oligonucleotides and thereby to control high-order structures and functions of DNAs.  (+info)

Biotransformation of hydroxylaminobenzene and aminophenol by Pseudomonas putida 2NP8 cells grown in the presence of 3-nitrophenol. (5/178)

Biotransformation products of hydroxylaminobenzene and aminophenol produced by 3-nitrophenol-grown cells of Pseudomonas putida 2NP8, a strain grown on 2- and 3-nitrophenol, were characterized. Ammonia, 2-aminophenol, 4-aminophenol, 4-benzoquinone, N-acetyl-4-aminophenol, N-acetyl-2-aminophenol, 2-aminophenoxazine-3-one, 4-hydroquinone, and catechol were produced from hydroxylaminobenzene. Ammonia, N-acetyl-2-aminophenol, and 2-aminophenoxazine-3-one were produced from 2-aminophenol. All of these metabolites were also found in the nitrobenzene transformation medium, and this demonstrated that they were metabolites of nitrobenzene transformation via hydroxylaminobenzene. Production of 2-aminophenoxazine-3-one indicated that oxidation of 2-aminophenol via imine occurred. Rapid release of ammonia from 2-aminophenol transformation indicated that hydrolysis of the imine intermediate was the dominant reaction. The low level of 2-aminophenoxazine-3-one indicated that formation of this compound was probably due to a spontaneous reaction accompanying oxidation of 2-aminophenol via imine. 4-Hydroquinone and catechol were reduction products of 2- and 4-benzoquinones. Based on these transformation products, we propose a new ammonia release pathway via oxidation of aminophenol to benzoquinone monoimine and subsequent hydrolysis for transformation of nitroaromatic compounds by 3-nitrophenol-grown cells of P. putida 2NP8. We propose a parallel mechanism for 3-nitrophenol degradation in P. putida 2NP8, in which all of the possible intermediates are postulated.  (+info)

Metabolism of para-aminophenol by rat hepatocytes. (6/178)

Autoxidation of para-aminophenol (PAP) has been proposed to account for the selective nephrotoxicity of this compound. However, other studies suggest that hepatic metabolites of PAP rather than the parent compound may be responsible for renal damage. These studies were designed to investigate PAP metabolism in isolated hepatocytes. We synthesized several proposed metabolites for analysis by HPLC/mass spectrometry and compared those results with HPLC/mass spectrometric analyses of metabolites found after incubating hepatocytes with PAP. Hepatocytes prepared from male Sprague-Dawley rats were incubated in Krebs-Henseleit buffer at 37 degrees C for 5 h with 2.3 mM PAP under an atmosphere of 5% CO2/95% O2. Aliquots were withdrawn at 0.1 h of incubation and then hourly through 5 h of incubation. Reactions were terminated by the addition of acetonitrile. Hepatocyte viability was unaltered with PAP present in the incubation medium. We found that hepatocytes converted PAP to two major metabolites (PAP-GSH conjugates and PAP-N-acetylcysteine conjugates) and several minor metabolites [PAP-O-glucuronide, acetaminophen (APAP), APAP-O-glucuronide, APAP-GSH conjugates, and 4-hydroxyformanilide]. Preincubating hepatoyctes with 1-aminobenzotriazole, an inhibitor of cytochromes P450, did not alter the pattern of PAP metabolism. In conclusion, we found that PAP was metabolized in hepatocytes predominantly to PAP-GSH conjugates and PAP-N-acetylcysteine conjugates in sufficient quantities to account for the nephrotoxicity of PAP.  (+info)

Stimulation of defective Gunn-rat liver uridine diphosphate glucuronyltransferase activity in vitro by alkyl ketones. (7/178)

Addition of alkyl ketone (10mM) to Gunn-rat liver homogenates increased UDP-glucuronyltransferase activity towards 2-aminophenol by 10--20 fold, up to enhanced values of enzyme activity observed with similarly treated Wistar-rat liver homogenates. Alkyl ketones also activate the defective enzyme purified from Gunn-rat liver. This genetic deficiency of UDP-glucuronyltransferase activity is no longer apparent when assayed in the presence of alkyl ketones.  (+info)

Metabonomics: evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. (8/178)

The purpose of this study was to evaluate the feasibility of metabonomics technology for developing a rapid-throughput toxicity screen using 2 known hepatotoxicants: carbon tetrachloride (CCl(4)) and alpha-naphthylisothiocyanate (ANIT) and 2 known nephrotoxicants: 2-bromoethylamine (BEA) and 4-aminophenol (PAP). In addition, the diuretic furosemide (FURO) was also studied. Single doses of CCl(4) (0.1 and 0.5 ml/kg), ANIT (10 and 100 mg/kg), BEA (15 and 150 mg/kg), PAP (15 and 150 mg/kg) and FURO (1 and 5 mg) were administered as single IP or oral doses to groups of 4 male Wistar rats/dose. Twenty-four-h urine samples were collected pretest, daily through Day 4, and on Day 10 (high dose CCl(4) and BEA only). Blood samples were taken on Days 1, 2, and 4 or 1, 4, and 10 for clinical chemistry assessment, and the appropriate target organ was examined microscopically. NMR spectra of urine were acquired and the data processed and subjected to principal component analyses (PCA). The results demonstrated that the metabonomic approach could readily distinguish the onset and reversal of toxicity with good agreement between clinical chemistry and PCA data. In at least 2 instances (ANIT and BEA), PCA analysis suggested effects at low doses, which were not as evident by clinical chemistry or microscopic analysis. Furosemide, which had no effect at the doses employed, did not produce any changes in PCA patterns. These data support the contention that the metabonomic approach represents a promising new technology for the development of a rapid throughput in vivo toxicity screen.  (+info)

China 2 Aminophenol, China 2 Aminophenol Suppliers and Manufacturers Directory - Source a Large Selection of 2 Aminophenol Products at from China Alibaba.com
... aims at providing comprehensive data on n,o-diacetyl-4-aminophenol market globally
Nominated Substances: 2-Acetylamino-4-methylphenol, N-Acetyl-m-aminophenol, 5-(4-Aminobenzamido)-2,3-cresotic acid, 2-Amino-4-chloro-5-nitrophenol, 2-Amino-4-chloro-6-nitrophenol, 2-Amino-6-chloro-4-nitrophenol, 2-Amino-4-chlorophenol, 6-Amino-4-chloro-1-phenol-2-sulfonic acid, 5-Amino-o-cresol, 2-Amino-4,6-dichlorophenol, 2-Amino-4,6-dinitrophenol, 4-Amino-4-hydroxy-3-methyl-diphenylamine, 2-Amino-4-methylphenol, 3-Amino-4-methylphenol, 2-Amino-4-(methylsulfonyl)phenol, 2-Amino-3-nitro-4-methylphenol, 2-Amino-5-nitro-4-methylphenol, 4-Amino-2-nitrophenol, 2-Amino-6-nitro-1-phenol-4-sulfonic acid, 6-Amino-4-nitro-1-phenol-2-sulfonic acid, 3-Aminophenol, p-Aminophenol, 2-Amino-1-phenol-4-sulfonic acid, 3-Amino-5-sulfosalicylic acid, 5-Amino-3-sulfosalicylic acid, 2-Amino-3,4,6-trichlorophenol, 4-(3-Carbazoylamino)phenol, 4-Chloro-2-(2,4-dinitroanilino)phenol, 5-Diethylamino-2-nitroso-4-methylphenol, 5-Diethylamino-2-nitrosophenol, 3-Diethylaminophenol, 3-Dimethylamino-4-methylphenol, ...
Disclosed are epoxy resin compositions comprising at least one polyglycidyl derivative of an aminophenol having the structure ##STR1## and at least one biphenyl anhydride having the structure ##STR2## wherein m is 1 or 2; wherein A is selected from the group consisting of ##STR3## WHEREIN EACH R.sup.o is individually a monovalent radical selected from the group consisting of hydrogen, halogen, hydroxy, alkyl radical having from 1 to 5 carbon atoms, alkoxy radical having from 1 to 5 carbon atoms and ##STR4## wherein R.sup.1 is an alkyl radical having from 1 to 5 carbon atoms; and wherein each R.sup.2 is individually a monovalent radical selected from the group consisting of hydrogen, halogen, alkyl radical having from 1 to 5 carbon atoms, --NO.sub.2, --COOH --SO.sub.3 H, and --NH.sub.2. The compositions are useful in such applications as molding resins, laminates, adhesives, coatings, and the like. The disclosed epoxy resin-anhydride
The kinetics of the auto-oxidation of 2-aminophenol (OAP) to 2-amino-phenoxazin-3-one (APX) was followed in air-saturated aqueous solutions and the influence of temperature and pH on the auto-oxidation rate was studied. The kinetic analysis was based on a spectrophotometric method following the increase of the absorbance of APX. The process follows first order kinetics according to the rate law-d[OAP]/dt=k′[OAP]. The experimental data, within the pH range 4-9.85, were analyzed using both differential and incremental methods. The temperature variation of the overall rate constant was studied at pH=9.85 within the range 25-50°C and the corresponding activation energy was evaluated ...
3-Aminophenol sulfate (2:1) | C12H16N2O6S | CID 163205 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.
This was a phase 3 study in subjects with cystic fibrosis (CF) age 12 years and older who have a G551D-CFTR mutation and percent predicted forced expiratory volumn in 1 second (FEV1) between 40% and 90%.. Based on in vitro studies and pharmacologic, pharmacokinetic (PK), and safety profiles, ivacaftor was selected for clinical development as a possible treatment for patients with CF. Patients with the G551D mutation were the targeted population for this study because ivacaftor is a potentiator of the gating function of the CFTR protein, and the most prevalent mutation with a gating defect in CF is the G551D mutation.. This study was designed to further evaluate the efficacy of ivacaftor in subjects with CF who have a G551D-CFTR gene mutation and to evaluate safety in this population over a longer period than previously studied. ...
In our case report we illustrate a positive effect of ivacaftor on the sinonasal pathology in a 17 year old patient with CF. Her CF genotype showed a heterozygous deltaF508/S1251N mutation, in which the S1251N mutation is a type III mutation and can therefore be influenced by ivacaftor. In addition to her pulmonary symptoms she chronically suffered from headaches and nasal obstruction, most likely caused by chronic rhinosinusitis. During these complaints two CT-sinuses were performed (fig. 1A and 1B), showing opacification of all paranasal sinuses. Despite accurate treatment of the rhinosinusitis, with nasal irrigations, nasal steroids complaints persisted. After 5 months of ivacaftor use, a new CT-sinus (fig. 1C) showed complete resolution of the opacification of the paranasal sinuses and a decrease in symptoms of sinonasal disease. This positive effect of ivacaftor on sinonasal pathology seems promising, therefore more research is needed to evaluate the effect of ivacaftor on the upper airways ...
The purpose of this study was to evaluate the safety and efficacy of ivacaftor in participants with cystic fibrosis (CF) who were aged 12 years or older and were homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic adenosine monophosphate (AMP)-dependent protein kinase A (PKA) activation ...
SHIJIAZHUANG DINGMIN PHARMACEUTICAL SCIENCES CO., LTD. - Ivacaftor Powder/ VX-770, Cas:873054-44-5 Manufacturer, Ivacaftor Powder/ VX-770, Cas:873054-44-5 Supplier, Ivacaftor Powder/ VX-770, Cas:873054-44-5 Exporter from Shijiazhuang, Hebei, China
A Phase II safety trial was carried out between April 2007 and August 2008 to study the safety and efficacy of ivacaftor in CF patients with Genotype G551D.. Another Phase II trial for ivacaftor included the DISCOVER study. It enrolled 140 patients who were 12 years or older who had two copies of the F508del-CFTR mutation. The study started in August 2009 and was completed in July 2010.. NDA and MAA submission was based on the DISCOVER and two Phase III trials - ENVISION and STRIVE.. ENVISION was carried out in 52 children aged between six and 11. Results from the study indicated that kalydeco was effective in improving lung function in patients. The mean absolute improvement in lung function in patients was 15.1% from baseline compared to placebo. The study also indicated increases in levels of sweat chloride levels.. The STRIVE study recruited 161 adolescents and adults aged 12 years or more suffering with CF. After 48 weeks of treatment with ivacaftor, the mean absolute improvement in lung ...
The cost of ivacaftor is US$311,000 per year, roughly similar to the price of other drugs for extremely rare diseases.[32] In the first nine months of its second year on the market (2014), ivacaftor sales were $339M, representing 54% of Vertexs product sales revenue. During the same period, total drug development expenses were $458M, most of which was spent on cystic fibrosis-related research.[33]. An editorial in JAMA called the price of ivacaftor "exorbitant", citing the support by the Cystic Fibrosis Foundation in its development and the contribution made by fundamental scientific research performed by the National Institutes of Health and relied upon by Vertex in its cystic fibrosis drug discovery programs.[34] The company responded in an email that "while publicly funded academic research provided important early understanding of the cause of cystic fibrosis, it took Vertex scientists 14 years of their own research, funded mostly by the company, before the drug won approval."[35]. The ...
Metalloproteins utilize O2 as an oxidant, and they often achieve a 4-electron reduction without H2O2 or oxygen radical release. Several proteins have been designed to catalyze one or two-electron oxidative chemistry, but the de novo design of a protein that catalyzes the net 4-electron reduction of O2 has not been reported yet. We report the construction of a diiron-binding four-helix bundle, made up of two different covalently linked ?2 monomers, through click chemistry. Surprisingly, the prototype protein, DF-C1, showed a large divergence in its reactivity from earlier DFs (DF: due ferri, two iron). DFs release the quinone imine and free H2O2 in the oxidation of 4-aminophenol in the presence of O2, whereas FeIII-DF-C1 sequesters the quinone imine into the active site, and catalyzes inside the scaffold an oxidative coupling between oxidized and reduced 4-aminophenol. The asymmetry of the scaffold allowed a fine-engineering of the substrate binding pocket, that ensures selectivity.Not just a ...
Our main intermediates are Red base KD, Diphenyl ether, Biphenyl, 2-aminophenol, 4,4-Bis(chloromethyl)-1,1-biphenyl(BCMB), p(o,m)-toluic acid, Terephthalaldehyde, 4,4-Biphenyldicarboxaldehyde, 4,4-Dimethylbiphenyl, 3-Chloro-2-methylaniline, o-Anisaldehyde,Decahydronaphthalene, p-Toluoyl Chloride , 2-Chlorothioxanthone, Benzaldehyde-2-sulfonic acid sodium, p(o,m)-Tolunitrile, Ferrocene ...
This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canadas national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc. ...
Lumacaftor/ivacaftor was well tolerated; the safety profile was generally similar to that observed in larger lumacaftor/ivacaftor trials with older patients. Four patients discontinued (two because of drug-related adverse events: elevated liver transaminases, n = 1; rash, n = 1). No safety concerns were associated with spirometry. No significant changes in percent predicted FEV1 were observed (change from baseline at Week 24, +2.5 percentage points; 95% confidence interval [CI], -0.2 to 5.2; P = 0.0671). At Week 24, significant improvements from baseline were observed in sweat chloride (-24.8 mmol/L; 95% CI, -29.1 to -20.5; Pâ ...
Here a novel electrochemical method for the rapid detection of anti-HIV antibodies in serum is presented. The novelty lies in the combination of allosteric enzymes and coulometry to yield a fast, simple and reliable HIV diagnostic method. We have used a previously developed β-galactosidase enzyme that is efficiently activated by anti-HIV antibodies directed against a major B-cell epitope of the gp41 glycoprotein. When these antibodies bind the enzyme, the 3D conformation changes positively affecting the performance of the active site and, consequently, the enzyme activity is stimulated. Using 4-aminophenyl β-d-galactopyranoside (PAPG) as substrate yields p-aminophenol (PAP), which is reversibly oxidised at a very mild potential, ca. 0.37 V vs. Ag/AgCl over a range of electrode materials within the working pH range of β-galactosidase. In the present case, photolithographically produced microelectrode arrays resulted in a detection limit of 4 μM for 4-aminophenol (PAP). The presence of ...
Product Name: para amino phenol Another Name: p-aminophenol, PAP, 4-Aminophenol (Structural formula:) C6H7NO (Molecular weight:) 109.13 CAS NO.: 123-30-8 Appearance: It is a beige to white crystal or powder Use: It is a very important intermediate products, widely used in medicine, pesticides, additives, dyes and many other industries Standard: Enterprise Standard Package: 25KG/Bag Mail ...
Cystic Fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes - one from each parent - to have CF. While there are many different types of CFTR mutations that can cause the disease, the vast majority of all people with CF have at least one F508del mutation. These mutations, which can be determined by a genetic test or genotyping test, lead to CF by creating non-working and/or too few CFTR proteins at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung ...
The FDA approval of Orkambi was based on results from two Phase III clinical studies, Traffic and Transport, which were conducted to determine the safety and efficacy of the drug.. The two studies enrolled more than 1,100 people with cystic fibrosis with two copies of the F508del mutation belonging to the group over the age of 12.. Results showed that subjects treated with Orkambi experienced statistically significant improvements in lung function. Improvements in body mass index (BMI) and reductions in pulmonary exacerbations were also experienced.. Patients were divided into two arms in both of the randomised, double-blind, placebo-controlled studies.. The subjects in one arm received lumacaftor (600mg once daily or 400mg every 12 hours) in combination with ivacaftor (250mg every 12 hours), while the other arm received a matched placebo for 24 weeks.. The primary endpoint was the absolute change from baseline in the percentage of predicted forced expiratory volume in one second (FEV1) at week ...
Vertex Pharmaceuticals' ivacaftor drug, to be marketed as Kalydeco, reduced the incidence of pulmonary flare-ups in cystic fibrosis patients by 55% compared with a placebo, trial results show. It helps those with a certain genetic mutation but could have broader significance, a doctor says.
In accordance with § 35a (para. 1, sentence 11) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the Ivacaftor report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical companys dossier ...
ORKAMBI (Lumacaftor,Ivacaftor) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
We,Suzhou City Xiangcheng Qingtai Fine Chemicals Co.,Ltd ,provide our product catalog : China 3-nitro-4-aminophenol, 3-nitro-4-hydroxyethylaminophenol, China 3-nitro-4-hydroxypropylaminophenol, 2-chloro-5-nitro aniline, China 2-methyl-6-chloro aniline,
Bimetallic nanoparticles have attracted significant attention as their electrochemical and catalytic properties being superior to those of the individual component nanoparticles. In this study, gold-silver hybrid nanoparticles (AuAgNPs) with an Aucore-Agshell nanostructure were successfully synthesized on zinc oxide (ZnO) whiskers. The as-prepared nanocatalyst, denoted [email protected] whisker, exhibits an excellent catalytic efficiency in the aqueous reduction of 4-nitrophenol to 4-aminophenol; the turnover frequency was up to 40 times higher than that of each component nanoparticle. Their unique features were attributed to the electronic ligand effect at the bimetallic interface. In addition, the AuAgNPs were synthesized on a ZnO whisker-containing paper with a fiber-network microstructure, which was prepared via a papermaking technique. The paper-structured AuAgNPs composite possessed both a paper-like practical utility and a good catalytic performance. Furthermore, the on-paper synthesis process for
An antioxidant, (as the name suggests), is a molecule that inhibits the oxidation of other molecules. Its THR chemical compounds are added to certain foods, natural and synthetic rubbers, gasolines or other substances, to inhibit its autoxidation. Oxidation is essentially a chemical reaction, involving the loss of electrons or succeeding stage of the oxidation process resulting in the production of free radicals. Antioxidants terminate these chain reactions by removing free radical intermediates, and inhibit other oxidation reactions. They do this by being oxidized themselves, and often reduci agents, for example, thiols ascorbic acid, or polyphenols. The most commonly used antioxidants are: aromatic amines, phenols, and aminophenols ...
Pseudomonas knackmussii B13 was the first strain to be isolated in 1974 that could degrade chlorinated aromatic hydrocarbons. This discovery was the prologue for subsequent characterization of numerous bacterial metabolic pathways, for genetic and biochemical studies, and which spurred ideas for pollutant bioremediation. In this study we determined the complete genome sequence of B13 using next generation sequencing technologies and optical mapping. Genome annotation indicated that B13 has a variety of metabolic pathways for degrading monoaromatic hydrocarbons including chlorobenzoate, aminophenol, anthranilate, and hydroxyquinol, but not polyaromatic compounds. Comparative genome analysis revealed that B13 is closest to Pseudomonas denitrificans and Pseudomonas aeruginosa. The B13 genome contains at least 8 genomic islands (prophages and integrative conjugative elements - ICE), which were absent in closely related pseudomonads. We confirm that two ICE are identical copies of the 103-kb ...
The Katz Group explores the synthesis of complex aryl ether and aryl amine macrocycles. Our favorite targets are aza- and oxacalixarenes and related cyclophanes, generated by condensation of diphenols, diaminobenzenes, and/or aminophenols with dihalogenated aromatics. We strive for chemical and operational simplicity; the representative examples shown below are all compounds produced in either a single step (2-component macrocycles) or one-pot manner (3-component macrocycles). We continue to explore properties and applications of these and other accessible ring systems.. ...
The diamagnetic title complexes were obtained from Ru(acac)(2)(CH3CN)(2) and 2-aminophenol or 2-aminothiophenol. X-ray structure analysis of (L-1)Ru(acac)(2) (L-1 = o-iminoquinone) revealed C-C intra-ring, C-O, and C-N distances which suggest a Ru-III-iminosemiquinone oxidation state distribution with antiparallel spin-spin coupling. One-electron oxidation and reduction of both title compounds to paramagnetic monocations [(L)Ru(acac)(2)](+) or monoanions [(L)Ru(acac)(2)](-) occurs reversibly at widely separated potentials (DeltaE , 1.3 V) and leads to low-energy shifted charge transfer bands. In comparison with clearly established Ru-II-semiquinone or Ru-III-catecholate systems the g tensor components 2.23 , g(1) , 2.09, 2.16 , g(2) , 2.07, and 1.97 , g(3) , 1.88 point to considerable metal contributions to the singly occupied MO, corresponding to Ru-III complexes with either o-quinonoid (--, cations) or catecholate-type ligands (--, anions) and only minor inclusion of Ru-IV- or ...
94 STAT. 2558. PUBLIC LAW 96-490-DEC. 2, 1980 (iv) by amending the article description for item 404.32 to read as follows: "Naphthalic anhydride; Phthalic acid; and 4-Sulfo-l,8-naphthalic anhydride"; (v) by striking out "p-Aminobenzoylaminonaphthalene sulfonic acid;" "Aminophenol, substituted;", "3-(N-Ethylanilino)propionic acid, methyl ester;", "l-(p-Nitrophenvl)-2amino-l,3-propanediol;", and "Toluidine carbonate; in item 404.84: (vi) by amending item 404.92- (I) by striking out "p-Acetaminobenzaldehyde;", (II) by inserting "3-(N-Ethylanilino)propionic acid, methyl ester;" immediately after "4-Dimethylaminobenzaldehyde;", (III) by inserting "l-(p-Nitrophenyl)-2-amino-l,3-propanediol;" immediately after "2-Methyl-p-anisidine [NH2=1];", (IV) by striking out "Nitra acid amide (1-Amino9,10-dihydro-N-(3-methoxypropyl)-4-nitro-9, lO-dioxo-2anthramide); and "; and (V) by inserting "; and Toluidine carbonate" immediately after "\-Phenylalanine"; (vii) by amending item 405.28- (I) by inserting ...
1L4N: Structural studies of the L-threonine-O-3-phosphate decarboxylase (CobD) enzyme from Salmonella enterica: the apo, substrate, and product-aldimine complexes.
... - Browse fuzing.com to find O-aminophenol sellers, suppliers, wholesalers, companies, manufacturers, exporters, factories.
Abstract CuCo2O4 spinel nanoparticles were successfully preparedvia a sol-gel method, which were firstly employed in catalytic reduction of p-nitrophenol to produce p-aminophenol. CuCo2O4...
This study is evaluating the safety and effectiveness of a new investigational medication called VX-561, an altered form of KALYDECO® (generic: ivacaftor), compared to the original ivacaftor.
-2013 investment focused on key development programs in cystic fibrosis, hepatitis C and autoimmune diseases- -First two Breakthrough Therapy Designations from U.S. FDA granted to ivacaftor monotherapy and to the combination regimen of VX-809 and ivacaftor for the treatment of cystic...
When it was approved, Vertexs drug made headlines for costing $259,000 a year. It treats a particular type of cystic fibrosis, and is taken twice a day. Cystic
Hi, I have been waiting 8 years for Ivacaftor to be approved for residual function CFTR mutations. The day finally came on May 17th and soon after, we had my son signed up and taking his first dose. We did this with a little trepidation based on the results of a small N-of-1 study (https://www.ncbi.nlm.nih.gov/pubmed/28068001) where Ivacaftor had the opposite effect for 2 of the people in the study; both with the A455E defect. I thought how can that be possible with all the preclinical work
Read about how to correctly administer KALYDECO oral granules. See Important Safety Information and full Prescribing Information.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites ...
See a video about the mechanism of action for ORKAMBI and download mechanism of action information for healthcare providers. See Important Safety Information and full Prescribing Information.
Orkambi: This is a combination product that contains two medications: ivacaftor and lumacaftor. It is used to treat cystic fibrosis (CF) in adults and adolescents over the age of 6 who have one of several possible mutations (a change) in their CFTR gene, the F508del mutation.
A combination of two drugs - lumacaftor and ivacaftor - improves lung function in children aged 6-11 with cystic fibrosis within 15 days of treatment, according to a phase 3 trial published in...
This phase IIb study is investigating the efficacy and safety of VX-661 in combination with ivacaftor, in patients with cystic fibrosis who are homozygous for
This phase IIa study will evaluate whether the addition of P-1037 to the combination of lumacaftor and ivacaftor in people with cystic fibrosis (CF) who have
In a big win for Cambridge-based Vertex Pharmaceuticals, the US Food and Drug Administration today approved the companys drug Kalydeco (ivacaftor) to treat a rare form of cystic fibrosis. The drug is approved for patients ages 6 and over who carry the G551D gene mutation, and the news follows the approval last year of Vertexs hepatitis C drug Incivek.
Kalydeco (ivacaftor) and lumacaftor address the underlying cause of CF rather than just symptoms of the disease, in which a missing or defective protein called CFTR results in poor flow of salt and water into and out of cells in the lungs. That causes a buildup of thick, sticky mucus that can lead to chronic lung infections, progressive lung damage and death at an early age ...
This information and facts can then be employed to re construct cell signaling events, transcription factors in volved Ivacaftor VX-770 and mechanisms particip
Mouse monoclonal antibody raised against a full-length recombinant EPN3. EPN3 (AAH01038.1, 1 a.a. ~ 208 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. (H00055040-M) - Products - Abnova
The present disclosure provides compositions and methods for the biosynthetic production of acetaminophen, p-aminophenol, and p-aminobenzoic acid and the purification of biologically derived acetaminophen.
Defects in cystic fibrosis transmembrane conductance regulator (CFTR) can cause cystic fibrosis (CF; MIM:602421), a common generalised disorder in Caucasians affecting the exocrine glands. CF results in an ionic imbalance that impairs clearance of secretions, not only in the lung, but also in the pancreas, gastrointestinal tract and liver. Wide-ranging manifestations of the disease include chronic lung disease, exocrine pancreatic insufficiency, blockage of the terminal ileum, male infertility and salty sweat. The class 3 mutations of CFTR such as G551D strongly decrease the time spent by CFTR in the open state (a gating defect). Results from 2-phase clinical trials using VX-770 (aka Ivacaftor), a CFTR potentiator, showed an increased CFTR channel open probability in G551D patients. Ivacaftor use showed improvements in CFTR and lung function of patients with at least one G551D allele (Accurso et al. 2010, Ramsey et al. 2011, Kapoor et al. 2014). In 2012, the FDA approved Ivacaftor (under the ...
Nimesulide; Aminophenols (anilines): Acetanilide. *AM-404 (N-arachidonoylaminophenol). *Bucetin. *Paracetamol (acetaminophen). ...
Nimesulide; Aminophenols (anilines): Acetanilide. *AM-404 (N-arachidonoylaminophenol). *Bucetin. *Paracetamol (acetaminophen). ...
Nimesulide; Aminophenols (anilines): Acetanilide. *AM-404 (N-arachidonoylaminophenol). *Bucetin. *Paracetamol (acetaminophen). ...
Nimesulide; Aminophenols (anilines): Acetanilide. *AM-404 (N-arachidonoylaminophenol). *Bucetin. *Paracetamol (acetaminophen). ...
Nimesulide; Aminophenols (anilines): Acetanilide. *AM-404 (N-arachidonoylaminophenol). *Bucetin. *Paracetamol (acetaminophen). ...
Nimesulide; Aminophenols (anilines): Acetanilide. *AM-404 (N-arachidonoylaminophenol). *Bucetin. *Paracetamol (acetaminophen). ...
Nimesulide; Aminophenols (anilines): Acetanilide. *AM-404 (N-arachidonoylaminophenol). *Bucetin. *Paracetamol (acetaminophen). ...
Nimesulide; Aminophenols (anilines): Acetanilide. *AM-404 (N-arachidonoylaminophenol). *Bucetin. *Paracetamol (acetaminophen). ...
Particularly useful are derivatives of aminophenol. Metal complex dyes using copper or chromium are commonly used for producing ...
In the Bamberger rearrangement N-phenylhydroxylamines rearrange to 4-aminophenols. The nucleophile is water. In the Sandmeyer ...
strain 10d: A different modified meta-cleavage pathway for 2-aminophenols". Biosci. Biotechnol. Biochem. 70 (11): 2653-2661. ...
... can be synthesized by reacting p-aminophenol with chloracetic acid in a solvent. Other uses of glycin can be found in ... Glycin is related to 4-aminophenol and Metol. Compared to Metol, glycin has a carboxyl group attached to the methyl group of ... Glycin, or N-(4-hydroxyphenyl)glycine, is N-substituted p-aminophenol. It is a photographic developing agent used in classic ...
ACETYL-P-AMINOPHENOL; AKOS BBS-00008094; APAP; N-(4-HYDROXYPHENYL)ACETAMIDE; N-ACETYL-4-AMINOPHENOL; N-ACETYL-P-AMINOPHENOL; P- ...
He worked on formulations based on p-phenylenediamine and p-aminophenol, among other aromatic amines. He discovered a useful ... formulation based on p-aminophenol. On 27 January 1891, a German patent application describing and claiming it was filed. That ...
Hypochlorous acid gives 4-aminophenol and para-amino diphenylamine. Oxidation with persulfate affords a variety of polyanilines ...
O-protonation 3 can form the nitrenium ion 4, which can react with nucleophiles (H2O) to form the desired 4-aminophenol 5. ... Part 4. Rearrangement of Sterically Hindered Phenylhydroxylamines to 4-Aminophenols in Aqueous Sulphuric Acid Solution". ... which will rearrange to give 4-aminophenols. It is named for the German chemist Eugen Bamberger (1857-1932). N- ...
4-Aminophenol may be obtained by the amide hydrolysis of paracetamol. 4-Aminophenol prepared this way, and related to the ... The nitro group is then reduced to an amine, giving 4-aminophenol. Finally, the amine is acetylated with acetic anhydride. ... It has been suggested that contamination of paracetamol with 4-aminophenol, the substance von Mering synthesised it from, may ... This reaction is also used to determine paracetamol in urine samples: After hydrolysis with hydrochloric acid, 4-aminophenol ...
It is reduced to 4-aminophenol, then acetylated with acetic anhydride. 4-Nitrophenol is used as the precursor for the ...
The mononitrated phenols are often hydrogenated to the corresponding aminophenols that are also useful industrially. 2,4- ...
2012). "Kinetic characterisation of o-aminophenols and aromatic o-diamines as suicide substrates of tyrosinase". Biochim. ... 2-diamine and 2-aminophenol, and 2,3-dihydroxybenzoic acid itself, tetrahydrofolic acid, analogues of pyrimidine and rhodanine ...
With heat, aminosalicylic acid is decarboxylated to produce CO2 and 3-aminophenol. PAS has been shown to be a pro-drug and it ... Vetuschi, C.; Ragno, G.; Mazzeo, P. (1988). "Determination of p-aminosalicylic acid and m-aminophenol by derivative UV- ...
Chemically, it is the amide formed from 4-aminophenol and arachidonic acid. AM404 was originally reported to be an endogenous ...
Finding that p-aminophenol conjugates were excreted, they refuted the earlier theories that the accumulation of this substance ... The role of p-aminophenol in the production of methemoglobinemia after acetanilid". Journal of Pharmacology and Experimental ...
3.0.CO;2-7. Jeong, J.-H.; Byoun, Y.-S. (2002). "Poly(styrene-alt-maleic anhydride)-4-aminophenol conjugate: synthesis and ...
Examples of Agent 1 include: Phenidone, Dimezone S, Metol, p-aminophenol, glycin, Eikonogen. These agents have nitrogen atoms ...
Aminophenol may refer to any of three isomeric chemical compounds: 2-Aminophenol 3-Aminophenol 4-Aminophenol They are ...
2-Aminophenol is an organic compound with the formula , C=6 , H=4 (OH)N, H=2 . Along with its isomer 4-aminophenol, it is an ... 2-Aminophenol (and its isomer, 4-aminophenol) is industrially synthesized by reducing the corresponding nitrophenol by hydrogen ... 2-Aminophenol has a variety of uses. As a reducing agent, it is marketed under the names of Atomal and Ortol to develop black- ... 2-Aminophenol is an intermediate in the synthesis of dyes. It is particularly useful in yielding metal-complex dyes when ...
... o-aminophenol) (POAP) film electrodes. It is divided into three parts. The first one ha ... Electropolymerization of o-aminophenol on Different Electrode Materials and in Different Electrolyte Media: Formation of Poly(o ... This review book is concerned with the synthesis, charge transport properties and practical applications of poly(o-aminophenol ...
p-aminophenol. Type of composition:. legal entity composition of the substance. State / form:. solid: bulk. Reference substance ... 4-aminophenol. Type of composition:. legal entity composition of the substance. State / form:. solid: particulate/powder. ...
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice ...
aminophenol (CHEBI:18112) / a phenol (2-AMINOPHENOL) Targets. Details1. Nicotinate-nucleotide--dimethylbenzimidazole ... O-aminophenol / Aniline or substituted anilines / Aminophenol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted ... 2-Aminophenol. PDB Entries. 1l4n. Clinical Trials. Clinical Trials Not Available. Pharmacoeconomics. Manufacturers. Not ... o-Aminophenols / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Primary amines / Organopnictogen ...
3-Aminophenol, p-Aminophenol, 2-Amino-1-phenol-4-sulfonic acid, 3-Amino-5-sulfosalicylic acid, 5-Amino-3-sulfosalicylic acid, 2 ... Nomination Summary for Salmonella assay for group of aminophenols (N82317). Nomination Summary for Salmonella assay for group ... Nominated Substances: 2-Acetylamino-4-methylphenol, N-Acetyl-m-aminophenol, 5-(4-Aminobenzamido)-2,3-cresotic acid, 2-Amino-4- ...
Browse fuzing.com to find O-aminophenol sellers, suppliers, wholesalers, companies, manufacturers, exporters, factories. ... O-aminophenol. You May Also Be Interested In: medicine packaging organic intermediate Appearance : nearly white powdered ...
China 2 Aminophenol Suppliers and Manufacturers Directory - Source a Large Selection of 2 Aminophenol Products at from China ... Tags: 2-aminophenol-4-sulfonamide , 98-32-8 , 2-aminophenol-4-sulfonamide 99% /cas: 98-32-8 Offer Them In Bulk ... Alibaba.com offers 248 2 aminophenol products. such as free samples. There are 248 2 aminophenol suppliers, mainly located in ... The top supplying country is China (Mainland), which supply 100% of 2 aminophenol respectively. aminophenol products are most ...
Crystal Structure of CobT complexed with 2-aminophenol. *DOI: 10.2210/pdb1l4n/pdb ...
Coupling of anilines to o-aminophenol groups derived from tyrosine residues is also described. The compatibility of this method ... A highly efficient protein bioconjugation method is described involving addition of anilines to o-aminophenols in the presence ... "Rapid Chemoselective Bioconjugation through Oxidative Coupling of Anilines and Aminophenols." Journal of the American Chemical ...
3-Aminophenol sulfate (2:1) , C12H16N2O6S , CID 163205 - structure, chemical names, physical and chemical properties, ...
N-Methyl-p-aminophenol sulfate , C14H20N2O6S , CID 5930 - structure, chemical names, physical and chemical properties, ...
2-aminophenol , ,ALOGPS_LOGP, 0.35 , ,JCHEM_LOGP, 0.8407545403333332 , ,ALOGPS_LOGS, 0.02 , ,JCHEM_MDDR_LIKE_RULE, 0 , ,JCHEM_ ...
1L4N: Structural studies of the L-threonine-O-3-phosphate decarboxylase (CobD) enzyme from Salmonella enterica: the apo, substrate, and product-aldimine complexes.
3-({5-Bromo-4-[pyrrolidin-1-yl]pyrimidin-2-yl}amino)phenol by Alan M. Jones ... Jones, A.M. 3-({5-Bromo-4-[pyrrolidin-1-yl]pyrimidin-2-yl}amino)phenol. Molbank 2015, 2015, M859. ... "3-({5-Bromo-4-[pyrrolidin-1-yl]pyrimidin-2-yl}amino)phenol." Molbank 2015, no. 2: M859. ... 3-({5-Bromo-4-[pyrrolidin-1-yl]pyrimidin-2-yl}amino)phenol. Molbank. 2015; 2015(2):M859. ...
Specific Chemical Reactivities of Spatially Separated 3-Aminophenol Conformers with Cold Ca+ Ions ... Specific Chemical Reactivities of Spatially Separated 3-Aminophenol Conformers with Cold Ca+ Ions ... Specific Chemical Reactivities of Spatially Separated 3-Aminophenol Conformers with Cold Ca+ Ions ... Specific Chemical Reactivities of Spatially Separated 3-Aminophenol Conformers with Cold Ca+ Ions ...
Notes: Sales, means the sales volume of 2-Aminophenol Revenue,... ... Check for Discount on United States 2-Aminophenol Market Report ... 1 2-Aminophenol Overview. 1.1 Product Overview and Scope of 2-Aminophenol. 1.2 Classification of 2-Aminophenol. 1.2.1 Type I. ... 2.4 2-Aminophenol Market Competitive Situation and Trends. 2.4.1 2-Aminophenol Market Concentration Rate. 2.4.2 2-Aminophenol ... United States 2-Aminophenol Market Report 2016 Table of Contents. United States 2-Aminophenol Market Report 2016. ...
... derivative of an aminophenol having the structure ##STR1## and at least one biphenyl anhydride having the structure ##STR2## ... The preferred polyglycidyl derivative of aminophenol at the present time is triglycidylp-aminophenol (m is 1).. The biphenyl ... An epoxy resin composition according to claim 18 wherein said polyglycidyl aminophenol is triglycidyl p-aminophenol.. 21. An ... An epoxy resin composition according to claim 24 wherein said polyglycidyl aminophenol is triglycidyl p-aminophenol.. 26. An ...
O-DIACETYL-4-AMINOPHENOL (CAS 2623-33-8) Market Research Report 2018 aims at providing comprehensive data on n,o-diacetyl-4- ... N,o-diacetyl-4-aminophenol market forecast. 6. N,O-DIACETYL-4-AMINOPHENOL MARKET PRICES. 6.1. N,o-diacetyl-4-aminophenol prices ... N,o-diacetyl-4-aminophenol prices in other regions. 7. N,O-DIACETYL-4-AMINOPHENOL END-USE SECTOR 7.1. N,o-diacetyl-4- ... 3. N,O-DIACETYL-4-AMINOPHENOL MANUFACTURING METHODS. 4. N,O-DIACETYL-4-AMINOPHENOL PATENTS. Abstract. Description. Summary of ...
1.4 Para Amino Phenol Industry Overview. Chapter Two Para Amino Phenol International and China Market Analysis. 2.1 Para Amino ... Chapter One Para Amino Phenol Industry Overview. 1.1 Para Amino Phenol Definition. 1.2 Para Amino Phenol Classification and ... 5.1 Para Amino Phenol Product Specifications. 5.2 Para Amino Phenol Manufacturing Process Analysis. 5.3 Para Amino Phenol Cost ... 2.2.5 Para Amino Phenol China Market Development Trend. 2.2.6 China Para Amino Phenol New Project and Project Plan. 2.3 Para ...
Merrill, W.G.; Crim, F.; Case, A.; Heid, C.G. IR-DRIVEN DYNAMICS OF THE 3-AMINOPHENOL-AMMONIA COMPLEX. Proceedings of the ... We report on gas-phase experiments investigating the predissociation and possible IR-driven isomerization of the 3-aminophenol- ... Ir-driven Dynamics Of The 3-aminophenol-ammonia Complex. Welcome to the IDEALS Repository. ... Ir-driven Dynamics Of The 3-aminophenol-ammonia Complex. Merrill, W G ...
Find quality 3-Aminophenol CAS:591-27-5 manufacturers, suppliers, exporters, importers, buyers, wholesalers,producers start ... Provide the most valuable information resources about 3-Aminophenol,CAS 591-27-5,Molecular Formula C6H7NO,structure, ... HYDROXYBENZENE 3-AMINOPHENOL 3-HYDROXYANILINE 5-AMINO-PHENOL AMINOPHENOL-3 LABOTEST-BB LTBB000485 M-AMINOPHENOL META AMINO ... DetailDesc: m-Amino phenol Name:m-Aminophenol Synonym: C.I. 76545 C.I. OXIDATION BASE 7 3-AMINO-1-HYDROXYBENZENE M- ...
Five arylene bisazo 3-aminophenols (IVa-e) and their corresponding polycondensates with formaldehyde (Va-e) were prepared and ... Syntheses and dyeing characteristics of arylene bisazo 3-aminophenols and their polycondensates with formaldehyde. ...
l N-benzyl-p-aminophenol hydrochloride 0.85 Cyan Color Developer 2 N-piperonyl-p-aminophenol hydrochloride 0 R5 50 3 6-(p- ... N-piperonyl-p-aminophenol EXAMPLE 1 A multilayer color photographic film was formed of the following layers (in the order given ... v Reproduced N0 Compensating developer (AP (3) l N-benzyl-p-aminophenol 1.05 0.63 l 5 g ig; 2 1.05 1.13 1.15 0.32 0.30 2 6-(p- ... N-benzyl-p-aminophenol is widely used as one such compensating developer. It is generally known that the compensating ...
  • The present disclosure relates compositions and methods for the biosynthetic production of medicinal supplements such as acetaminophen and intermediates including p-aminophenol, poly(p-aminophenol), and p-aminobenzoic acid (PABA). (google.com)
  • In August 2016, NICNAS, under its Inventory Multi-tiered Assessment and Prioritisation (IMAP) Scheme submitted a proposal to create a new entry for m -aminophenol in Schedule 6 for restriction in cosmetic and domestic products. (tga.gov.au)
  • The report then estimates 2016-2021 market development trends of 2-Aminophenol-4-(N-Ethyl)Sulfonamide industry. (reportsnreports.com)
  • The nitro group is then reduced to amine giving 4-aminophenol which is acetylated with acetic anhydride to produce acetaminophen. (google.com)
  • 59, 803-807 (1986)) disclose that the reaction of 1,4-cyclohexanedione and a secondary amine in the presence of an acid catalyst does not afford an aminophenol compound or if do, the yield is only 4 to 12%, and the main product of the reaction is an aniline compound. (allindianpatents.com)
  • While not generally considered an anti-inflammatory drug, acetaminophen (paracetamol, N-acetyl-para-aminophenol, APAP) has similar clinical indications to NSAIDs due to its analgesic and antipyretic properties [ 18 ] . (nnjournal.net)
  • A highly efficient protein bioconjugation method is described involving addition of anilines to o-aminophenols in the presence of sodium periodate. (harvard.edu)
  • Coupling of anilines to o-aminophenol groups derived from tyrosine residues is also described. (harvard.edu)
  • A pathway for the metabolism of 4-aminophenol in strain AK-5 was proposed based on the identification of three key metabolites by gas chromatography-mass spectrometry analysis. (asm.org)
  • Our aim was to elucidate a biodegradation pathway for 4-aminophenol by analyzing metabolites. (asm.org)
  • The beneficial effects of acetaminophen have been proposed to stem from its metabolites p-aminophenol and N-arachidonoylaminophenol (AM404), of which, AM404 possesses analgesic and antipyretic properties. (nnjournal.net)
  • Since AM404 has been previously demonstrated to attenuate NF-kB activation, it is likely that the protective effects of acetaminophen against adverse microglia activation are mediated by its metabolites p-aminophenol and AM404 inhibiting this transcription factor. (nnjournal.net)
  • Due to the adjacency of the amino and hydroxyl groups, 2-aminophenol readily forms heterocycles. (wikipedia.org)
  • Guliev, A. 2013-12-28 00:00:00 Polyconjugated oligomers containing aromatic links with hydroxyl and amino functional groups were synthesized by oxidative polycondensation of 4-aminophenol. (deepdyve.com)
  • A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group. (ebi.ac.uk)
  • On 31 January 2017, the Schedule 6 entry for m -aminophenol was removed by amendment from the 1 February 2017 Poisons Standard. (tga.gov.au)
  • m -Aminophenol was subsequently referred to the March 2017 ACCS meeting to enable a consultation process on the proposed scheduling. (tga.gov.au)
  • An application was submitted by the National Industrial Chemicals Notification and Assessment Scheme (NICNAS) to create a new Schedule 6 entry for m -aminophenol with an appropriate exemption cut-off for hair dye use. (tga.gov.au)
  • m-Aminophenol is used in oxidative hair dye formulations, which after mixing with hydrogen peroxide just prior to use. (jayorganics.com)
  • 8. An epoxy resin system according to claim 7 wherein said polyglycidyl aminophenol is triglycidyl p-aminophenol, said biphenyl anhydride is 3,3',4,4'-benzophenone tetacarboxylic dianhydride, and the ratio of anhydride equivalents to epoxideequivalents is in the range of 0.6-0.95:1. (patentgenius.com)
  • The ''Global and Chinese 2-Aminophenol-4-(N-Ethyl)Sulfonamide Industry, 2011-2021 Market Research Report'' is a professional and in-depth study on the current state of the global 2-Aminophenol-4-(N-Ethyl)Sulfonamide industry with a focus on the Chinese market. (reportsnreports.com)
  • The report provides key statistics on the market status of the 2-Aminophenol-4-(N-Ethyl)Sulfonamide manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. (reportsnreports.com)
  • Through the statistical analysis, the report depicts the global and Chinese total market of 2-Aminophenol-4-(N-Ethyl)Sulfonamide industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. (reportsnreports.com)
  • In the end, the report makes some important proposals for a new project of 2-Aminophenol-4-(N-Ethyl)Sulfonamide Industry before evaluating its feasibility. (reportsnreports.com)
  • Overall, the report provides an in-depth insight of 2011-2021 global and Chinese 2-Aminophenol-4-(N-Ethyl)Sulfonamide industry covering all important parameters. (reportsnreports.com)
  • 5.2 Market Competition of 2-Aminophenol-4-(N-Ethyl)Sulfonamide Industry by Country (USA, EU, Japan, Chinese etc. (reportsnreports.com)
  • This report is an essential reference for who looks for detailed information on Europe 2-Aminophenol-4-Sulfonamide market. (absolutereports.com)
  • In addition to the data part, the report also provides overview of 2-Aminophenol-4-Sulfonamide market, including classification, application, manufacturing technology, industry chain analysis and latest market dynamics. (absolutereports.com)
  • The basal medium containing 4-aminophenol was prepared by methods described previously ( 3 ). (asm.org)
  • The present disclosure provides compositions and methods for the biosynthetic production of acetaminophen, p-aminophenol, and p-aminobenzoic acid and the purification of biologically derived acetaminophen. (google.com)
  • The strategy uses o-aminophenols or o-catechols that are oxidized to active coupling species in situ using potassium ferricyanide. (nih.gov)
  • Several proteins werereacted with o-aminophenol-functionalized 5 kDa PEGunder the optimized reaction conditions (Figure 3). (nih.gov)
  • Para-aminophenol (PAP) Report by Material, Application, and Geography - Global Forecast to 2022 is a professional and comprehensive research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom,Japan, South Korea and China). (gosreports.com)
  • Subsequently, the control andtreated o-aminophenol samples were characterized by X-ray diffraction (XRD), Differential scanning calorimetry(DSC), Thermogravimetric analysis (TGA), surface area analysis, Fourier transform infrared (FT-IR) spectroscopy,and Ultra violet-visible spectroscopy analysis (UV-vis). (peerevaluation.org)
  • Protein modification with o-aminophenols. (nih.gov)
  • Succinate-glucose medium was a modified basal medium containing 1.0% (wt/vol) sodium succinate, 1.0% (wt/vol) d -glucose, and 0.04% (wt/vol) NH 4 NO 3 as the sole carbon and nitrogen sources instead of 4-aminophenol. (asm.org)
  • Only at basic pH in the presence of both the o-aminophenol substrate and the oxidant was modification observed.Additionally, the proline-terminal variant showed significantly improvedreactivity compared to that of the wild-type N-terminus. (nih.gov)
  • P-aminophenol and AM404 suppressed nitric oxide secretion from stimulated microglia more effectively than acetaminophen through pathways that were independent of COX inhibition, cannabinoid receptor type two (CB2) inhibition, and activation of transient receptor potential cation channel subfamily V member 1 (TRPV1). (nnjournal.net)